Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.58 |
| ▸ | CES1 | P23141 | 2/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | TERT | O14746 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | PPARD | Q03181 | 3/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | FABP4 | P15090 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8343681 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL8344661 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL8343680 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL19873069 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| Octane SCHEMBL16439984 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL2179345 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL2179341 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL170316 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL8344665 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 | |
| SCHEMBL29709266 | 1.00 | FAAH (0.58) | FAAHCES1DGKATERTPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114302741-A | Compositions and methods for treating autoimmune disorders | 密执安大学评议会 | 2022-04-08 | — | — | CN | claimed |
| US-12428634-B2 | Methods for extracting bioactive small RNAS from plants and mushrooms | MIRNAGREEN S.R.L. (IT) | 2025-09-30 | — | — | US | disclosed |
| CN-113454232-B | Modulation of REP protein Activity in Closed End DNA (CEDNA) production | 世代生物公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240344054-A1 | IMPROVED METHOD FOR SMALL RNA PURIFICATION | MIRNAGREEN S.R.L. (IT) | 2024-10-17 | — | — | US | disclosed |
| CN-118489008-A | Scalable and high purity cell-free synthesis of closed-end DNA vectors | 世代生物公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4384612-A1 | IMPROVED METHOD FOR SMALL RNA PURIFICATION | Mirnagreen S.r.l. (IT) | 2024-06-19 | — | — | EP | disclosed |
| CN-111867634-B | Enhancement of translocation of micro/nanoparticles across mucus layers using alginate oligomers | 阿尔吉法玛公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| CN-118043084-A | Compositions and methods for metal-containing formulations capable of modulating immune responses | 密执安大学评议会 | 2024-05-14 | — | — | CN | disclosed |
| CN-117940563-A | Improved small RNA purification process | 米尔纳格林有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2008148868-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148851-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148840-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148849-A2 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1893592-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006134317-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
| US-6255095-B1 | A NUCLEIC ACID THAT CODES FOR AN AMINO ACID SEQUENCE; THERAPY FOR RETINAL DEGENRATION | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2001-07-03 | — | — | US | disclosed |
| EP-0845981-A1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997046223-A1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | FAAH 2152/4885CES1 1267/4885DGKA 3/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | FAAH 962/4885CES1 147/4885DGKA 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.